Hi come on_老虎社区_美港股上老虎

2021-03-18

Hi come on

Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物科技每股收益超过预期 0.08 美元，营收超过预期</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":327181015,"tweetId":"327181015","gmtCreate":1616069930337,"gmtModify":1634527403620,"author":{"id":3561701296039483,"idStr":"3561701296039483","authorId":3561701296039483,"authorIdStr":"3561701296039483","name":"SDQwerty","avatar":"https://static.tigerbbs.com/91dd9a7c9982bff6f674211becf77da3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body>Hi come on</body></html>","htmlText":"<html><head></head><body>Hi come on</body></html>","text":"Hi come on","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/327181015","repostId":1141211447,"repostType":4,"repost":{"id":"1141211447","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616067847,"share":"https://www.laohunote.com/m/news/1141211447?lang=zh_CN&edition=full","pubTime":"2021-03-18 19:44","market":"us","language":"en","title":"Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物科技每股收益超过预期 0.08 美元，营收超过预期</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141211447","media":"Tiger Newspress","summary":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business U","content":"(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.<blockquote>（3月18日）传奇生物报告2020年第四季度和全年财务业绩和业务更新。</blockquote> <ul> <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li> <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"><blockquote><ul><li>Legend Biotech：第四季度 GAAP 每股收益为 -0.22 美元，超出 0.08 美元。</li><li>收入 4078 万美元（同比增长 109.7%）超过预期 2878 万美元。</li></ul></blockquote> Financial Results for the Quarter and Year Ended December 31, 2020<blockquote>截至2020年12月31日止季度及年度财务业绩</blockquote> Cash and Cash Equivalents and time deposits:<blockquote>现金及现金等价物及定期存款：</blockquote> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.<blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金和现金等价物以及约5000万美元的定期存款。</blockquote> Revenue<blockquote>收入</blockquote> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.<blockquote>截至2020年12月31日止三个月的收入为4080万美元，而截至2019年12月31日止三个月的收入为1950万美元。增加 2,130 万美元的主要原因是根据 Legend Biotech 与 Janssen 签订的协议，确认了更高金额的额外里程碑付款，相关的受限变量代价减免。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度的收入为5730万美元。同样，截至2020年12月31日止年度1,840万美元的增长主要是由实现更高金额的额外里程碑确认的收入推动的。传奇生物至今尚未从产品销售中产生任何收益。</blockquote> Research and Development Expenses<blockquote>研发开支</blockquote> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.<blockquote>截至2020年12月31日止三个月的研发费用为6690万美元，而截至2019年12月31日止三个月的研发费用为6610万美元。增加80万美元主要是由于员工福利费用和研发费用增加，被合作研发费用减少所抵销。截至2020年12月31日止年度的研发费用为2.322亿美元，而截至2019年12月31日止年度为1.619亿美元，增加了7030万美元。同比增长主要由于截至2020年12月31日止年度，临床试验数目增加、参与该等试验的患者数目增加以及研发候选产品数量增加所致。</blockquote> Loss for the Period<blockquote>期内亏损</blockquote> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.<blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，即每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，即每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，即每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，即每股0.66美元。</blockquote> Key Upcoming Milestones<blockquote>即将到来的主要里程碑</blockquote> <ul> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li> <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li> <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li> <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li> <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.<blockquote><ul><li>Legend Biotech 的合作者 Janssen 预计将于 2021 年上半年向 EMA 提交 cilta-cel 治疗成人 RRMM 的 MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel治疗成人RRMM。传奇生物预计申请将于二零二一年下半年提交。</li><li>Legend Biotech 的合作者 Janssen 预计将于 2021 年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准 cilta-cel 用于治疗患有 RRMM 的成人。</li><li>传奇生物预期于2021年在美国RR TCL启动LB1901的1期临床试验。</li><li>Legend Biotech 与 Janssen 合作，打算在 2021 年的主要医学会议上展示 CARTITUDE-1 和 CARTITUDE-2 研究的最新数据。</li><li>Legend Biotech 预计将于 2021 年发布 LEGEND-2 研究的临床数据更新，以支持研究人员。</li></ul>随著全球COVID-19疫情持续演变，传奇生物持续监察其营运情况，并已采取重大措施保障供应链、营运、员工及临床试验的执行。鉴于动态的全球形势，Legend Biotech指出，某些临床试验时间表可能会受到影响。</blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物科技每股收益超过预期 0.08 美元，营收超过预期</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech EPS beats by $0.08, beats on revenue<blockquote>传奇生物科技每股收益超过预期 0.08 美元，营收超过预期</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\nTiger Newspress \n2021-03-18 19:44\n</div>\n</a>\n</h4>\n</header>\n<article>\n(March 18)&nbsp;Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.<blockquote>（3月18日）传奇生物报告2020年第四季度和全年财务业绩和业务更新。</blockquote> <ul> <li>Legend Biotech&nbsp;: Q4 GAAP EPS of -$0.22beats by $0.08.</li> <li>Revenue of $40.78M (+109.7% Y/Y)beats by $28.78M.</li> </ul> <img src=\"https://static.tigerbbs.com/03aed76701fd868589414ae62671e72a\" tg-width=\"685\" tg-height=\"498\"><blockquote><ul><li>Legend Biotech：第四季度 GAAP 每股收益为 -0.22 美元，超出 0.08 美元。</li><li>收入 4078 万美元（同比增长 109.7%）超过预期 2878 万美元。</li></ul></blockquote> Financial Results for the Quarter and Year Ended December 31, 2020<blockquote>截至2020年12月31日止季度及年度财务业绩</blockquote> Cash and Cash Equivalents and time deposits:<blockquote>现金及现金等价物及定期存款：</blockquote> As of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.<blockquote>截至2020年12月31日，传奇生物拥有约4.557亿美元的现金和现金等价物以及约5000万美元的定期存款。</blockquote> Revenue<blockquote>收入</blockquote> Revenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.<blockquote>截至2020年12月31日止三个月的收入为4080万美元，而截至2019年12月31日止三个月的收入为1950万美元。增加 2,130 万美元的主要原因是根据 Legend Biotech 与 Janssen 签订的协议，确认了更高金额的额外里程碑付款，相关的受限变量代价减免。截至2020年12月31日止年度的收入为7570万美元，而截至2019年12月31日止年度的收入为5730万美元。同样，截至2020年12月31日止年度1,840万美元的增长主要是由实现更高金额的额外里程碑确认的收入推动的。传奇生物至今尚未从产品销售中产生任何收益。</blockquote> Research and Development Expenses<blockquote>研发开支</blockquote> Research and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.<blockquote>截至2020年12月31日止三个月的研发费用为6690万美元，而截至2019年12月31日止三个月的研发费用为6610万美元。增加80万美元主要是由于员工福利费用和研发费用增加，被合作研发费用减少所抵销。截至2020年12月31日止年度的研发费用为2.322亿美元，而截至2019年12月31日止年度为1.619亿美元，增加了7030万美元。同比增长主要由于截至2020年12月31日止年度，临床试验数目增加、参与该等试验的患者数目增加以及研发候选产品数量增加所致。</blockquote> Loss for the Period<blockquote>期内亏损</blockquote> For the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.<blockquote>截至2020年12月31日的三个月，净亏损为5780万美元，即每股0.22美元，而截至2019年12月31日的三个月净亏损为6390万美元，即每股0.32美元。截至2020年12月31日的年度净亏损为3.035亿美元，即每股1.28美元，而截至2019年12月31日的年度净亏损为1.33亿美元，即每股0.66美元。</blockquote> Key Upcoming Milestones<blockquote>即将到来的主要里程碑</blockquote> <ul> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.</li> <li>Legend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.</li> <li>Legend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.</li> <li>Legend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.</li> <li>Legend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.</li> <li>Legend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.</li> </ul> As the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.<blockquote><ul><li>Legend Biotech 的合作者 Janssen 预计将于 2021 年上半年向 EMA 提交 cilta-cel 治疗成人 RRMM 的 MAA。</li><li>传奇生物打算使用CARTIFAN-1研究的数据来支持向中国药品审评中心（CDE）提交的监管文件，寻求批准cilta-cel治疗成人RRMM。传奇生物预计申请将于二零二一年下半年提交。</li><li>Legend Biotech 的合作者 Janssen 预计将于 2021 年下半年向日本厚生劳动省（JMHLW）提交新药申请（NDA），寻求批准 cilta-cel 用于治疗患有 RRMM 的成人。</li><li>传奇生物预期于2021年在美国RR TCL启动LB1901的1期临床试验。</li><li>Legend Biotech 与 Janssen 合作，打算在 2021 年的主要医学会议上展示 CARTITUDE-1 和 CARTITUDE-2 研究的最新数据。</li><li>Legend Biotech 预计将于 2021 年发布 LEGEND-2 研究的临床数据更新，以支持研究人员。</li></ul>随著全球COVID-19疫情持续演变，传奇生物持续监察其营运情况，并已采取重大措施保障供应链、营运、员工及临床试验的执行。鉴于动态的全球形势，Legend Biotech指出，某些临床试验时间表可能会受到影响。</blockquote>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEGN":"传奇生物"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141211447","content_text":"(March 18) Legend Biotech Reports Fourth Quarter and Full Year 2020 Financial Results and Business Update.\n\nLegend Biotech : Q4 GAAP EPS of -$0.22beats by $0.08.\nRevenue of $40.78M (+109.7% Y/Y)beats by $28.78M.\n\n\nFinancial Results for the Quarter and Year Ended December 31, 2020\nCash and Cash Equivalents and time deposits:\nAs of December 31, 2020, Legend Biotech had approximately $455.7 million of cash and cash equivalents and approximately $50.0 million in time deposits.\nRevenue\nRevenue for the three months ended December 31, 2020 was $40.8 million compared to $19.5 million for the three months ended December 31, 2019. The increase of $21.3 million was primarily due to revenue recognition of additional milestone payment achieved of higher amount pursuant to Legend Biotech’s agreement with Janssen and the associated constrained variable consideration is relieved. Revenue for the year ended December 31, 2020 was $75.7 million compared to $57.3 million for the year ended December 31, 2019. Similarly, the increase of $18.4 million for the year ended December 31, 2020 was primarily driven by revenue recognized from an additional milestone achieved of higher amount. Legend Biotech has not generated any revenue from product sales to date.\nResearch and Development Expenses\nResearch and development expenses for the three months ended December 31, 2020 were $66.9 million compared to $66.1 million for the three months ended December 31, 2019. This increase of $0.8 million was primarily due to an increase in employee benefit expense and research and development expense, net-off by a decrease in collaborative research and development expenses. Research and development expenses for the year ended December 31, 2020 was $232.2 million compared to $161.9 million for the year ended December 31, 2019 with a $70.3 million increase. The year-over-year increase was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the year ended December 31, 2020.\nLoss for the Period\nFor the three months ended December 31, 2020, net loss was $57.8 million, or $0.22 per share, compared to a net loss of $63.9 million, or $0.32 per share, for the three months ended December 31, 2019. Net loss was $303.5 million, or $1.28 per share, for the year ended December 31, 2020 compared to $133.0 million, or $0.66 per share, for the year ended December 31, 2019.\nKey Upcoming Milestones\n\nLegend Biotech’s collaborator, Janssen, anticipates submitting a MAA for cilta-cel for the treatment of adults with RRMM to the EMA in the first half of 2021.\nLegend Biotech intends to use the data from the CARTIFAN-1 study in support of a regulatory submission to the China Center for Drug Evaluation (CDE) seeking approval of cilta-cel for the treatment of adults with RRMM. Legend Biotech expects the submission of the application to occur in the second half of 2021.\nLegend Biotech’s collaborator, Janssen, anticipates submitting a New Drug Application (NDA) to the Japan Ministry of Health, Labor and Welfare (JMHLW) in the second half of 2021 seeking approval of cilta-cel for the treatment of adults with RRMM.\nLegend Biotech expects to initiate its Phase 1 clinical trial of LB1901 in RR TCL inthe United Statesin 2021.\nLegend Biotech, in collaboration with Janssen, intends to present updated data from the CARTITUDE-1 and data from CARTITUDE-2 studies at major medical conferences in 2021.\nLegend Biotech anticipates supporting investigators with publishing a clinical data update from LEGEND-2 study in 2021.\n\nAs the global COVID-19 pandemic continues to evolve, Legend Biotech has continuously monitored the situation in regards to its operations and has put significant measures in place to protect supply chain, operations, employees and the execution of clinical trials. Given the dynamic global situation, Legend Biotech notes that certain clinical trial timelines may be impacted.","news_type":1,"symbols_score_info":{"LEGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2124,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/327181015"}